Clinical Oncology, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil.
Support Care Cancer. 2012 Sep;20(9):2195-7. doi: 10.1007/s00520-012-1474-z. Epub 2012 May 4.
Tumor-induced osteomalacia (TIO) is a paraneoplastic bone mineral disturbance related to fibroblast growth factor 23 (FGF23) overproduction by the tumor, usually from mesenchymal origin. Such condition leads to high phosphate renal wasting and, consequently, to cumbersome symptoms as weakness, bone pain, and fractures.
Case report.
We report a case of an advanced castration-refractory prostate cancer patient, which developed severe hypophosphatemia with elevated phosphate excretion fraction. TIO was suspected, and increased levels of FGF23 reinforced such diagnosis. The patient died 4 months after being diagnosed with TIO.
This case suggests that TIO has a dismal prognosis in prostate cancer patients. The clinical oncology community must be aware about such disturbance that can be present in those patients with weakness, bone pain, and hypophosphatemia.
肿瘤相关性骨软化症（TIO）是一种与肿瘤过度产生成纤维细胞生长因子 23（FGF23）相关的副瘤性骨矿物质紊乱，肿瘤通常来源于间叶组织。这种情况会导致高磷肾性丢失，进而导致乏力、骨痛和骨折等严重症状。
病例报告。
我们报告了一例晚期去势抵抗性前列腺癌患者，该患者出现严重的低磷血症伴磷排泄分数升高。怀疑存在 TIO，且 FGF23 水平升高进一步支持该诊断。患者在诊断为 TIO 后 4 个月死亡。
该病例表明，TIO 对前列腺癌患者预后不良。临床肿瘤学界必须了解这种在伴有乏力、骨痛和低磷血症的患者中可能出现的紊乱。
